|
市場調查報告書
冠狀動脈型心臟病與其預防
Prevention of Coronary Heart Disease - Promoting Healthy Lifestyles
|
本報告已在2011年07月19日停止出版。
美國心臟協會（AHA）指出，美國死亡人口中約有 1/5 死於冠狀動脈型心臟病。心臟病大多起源於高血壓、高膽固醇症、肥胖、糖尿病、吸煙與運動不足等原因，在事前取得正確的知識，採取健康的生活態度即可能預防心臟病發生。
擅長多領域市調分析的英國專業公司 Datamonitor Corporation（總公司：倫敦），調查分析了冠狀動脈型心臟病與其預防方式後，出版了一本綜合報告書"Prevention of Coronary Heart Disease - Promoting Healthy Lifestyles"。
報告書內容包括：動脈硬化的定義、流行病學、死亡患者相關統計與治療成本、減低罹患風險的對策、生命週期觀察、藥物治療對罹患風險的影響、預防對策等等，內容綱要摘記如下：
Datamonitor Healthcare 簡介
摘要
動脈硬化相關概要
- 疾病定義
- 流行病學
- 動脈硬化與冠狀動脈型心臟病帶來的負擔
動脈硬化的預防
- 動脈硬化風險要素
- AHA 對冠狀動脈型心臟病預防的建議
- 治療取向的生命週期觀察
- 藥物治療
- 代謝症候群
- 代謝症候群定義
- 重要診斷基準
- 代謝症候群與冠狀動脈型心臟病
附錄
Overview
Introduction
According to the American Heart Association, coronary heart disease (CHD) caused one out of every five deaths in the US in 2002. However, the majority of CHD is preventable. Screening, lifestyle changes and drug therapy can reduce an individuals risk of CHD. This is particularly important where there is a clustering of risk factors in the same individual as seen in metabolic syndrome patients
Scope
- Understand the definition of atherosclerosis, its epidemiology, mortality statistics and the burden on healthcare spending
- Understand the risk factors which can be changed or treated to reduce the risk of atherosclerotic disease
- Learn about risk factor screening, global risk estimation and risk intervention measures including therapeutic lifestyle changes and drug therapy
- Appreciate the possibility of multiple risk factors being present in one individual as metabolic syndrome and the link to coronary heart disease
Report Highlights
Cardiovascular disease is the leading cause of mortality in the US and Europe. More than one in five deaths are from coronary heart disease (CHD). Moreover the cost of CHD is huge. The American Heart Association, estimates the cost will be $142 billion in 2005 and the British Heart Foundation estimates it costs the UK almost $14 billion per year
The majority of heart disease is preventable through education and identification of risk factors. These include hypertension, hypercholesterolemia, being overweight/obese, diabetes mellitus, smoking and physical inactivity. Guidelines promote a healthy diet, weight loss and physical activity, although drug therapy is recommended where insufficient
Metabolic syndrome is characterized by a cluster of risk factors in one individual. Central obesity and insulin resistance are considered important causative factors. This combination leads to a high risk of type 2 diabetes and cardiovascular disease with an accepted increase in risk of between 1.5 and two times
Reasons to Purchase
- Acquire data on the epidemiology of coronary heart disease to enable sizing of the market opportunity
- Understand how to target your product portfolio to the risk factors associated with coronary heart disease
- Understand the potential market in metabolic syndrome patients of targeting multiple risk factors in the same individual
ABOUT DATAMONITOR HEALTHCARE
- About the Cardiovascular pharmaceutical analysis team
EXECUTIVE SUMMARY
- Introduction
- Scope and coverage of the Brief
- Key findings
ATHEROSCLEROSIS OVERVIEW
- Disease definition
- Epidemiology
- Burden of atherosclerosis and coronary heart disease
PREVENTION OF ATHEROSCLEROSIS
- Atherosclerotic risk factors
- Hypertension
- Hypercholesterolemia
- Overweight and obesity
- Diabetes
- Smoking
- AHA recommendations for the prevention of coronary heart disease
- Risk factor screening
- Global risk estimation
- Risk intervention
- Blood pressure control
- Blood lipid management
- Weight management
- Dietary intake
- Physical activity
- Smoking
- Aspirin
- Diabetes mellitus
- Therapeutic lifestyle changes
- Drug therapy
- Antihypertensives
- Statins
- Obesity drugs
- Antidiabetics
- Metabolic syndrome
- Metabolic syndrome definition
- Clinical criteria for diagnosis
- Metabolic syndrome and coronary heart disease
APPENDIX
- Bibliography
- Research methodology
- Disclaimer
- List of Tables
- Table 1: Epidemiology of cardiovascular disease, coronary heart disease and stroke in the US in 2002
- Table 2: Disability and mortality burdens of heart disease and stroke in the seven major markets in 2002
- Table 3: ATP III diagnostic criteria for metabolic syndrome
- Table 4: WHO working criteria for metabolic syndrome
- Table 5: IDF diagnostic criteria for metabolic syndrome
|
